

Cloud-based Solution for Real-time Reporting of Cancer Data

Joseph D. Rogers, MS

Team Lead Informatics, Data Science, and Applications Team (IDSAT) Cancer Surveillance Branch Division of Cancer Prevention and Control

CDC/NPCR Program Review

April 24, 2019





Problem Statement, Need, and Solution



Problem Statement

- Current data collection and reporting methods are hindered by manual processes
- Result is inherently needless time lags and costly inefficiencies



- Overarching need for more timely cancer incidence data for
- Faster identification of cancer cases for evaluation and improvement of cancer control strategies
- Better-informed decisions about where resources need to be allocated for cancer prevention, control, and treatment



Solution

- Removal of inefficiencies to move from publishing on 24 month to realtime data
- Use of cloud-based platform to achieve real-time reporting to the central cancer registry

3 Division for Cancer Prevention and Control

Current State





Current State: National Program of Cancer Registries (NPCR) Information Flow



6 Division for Cancer Prevention and Control

Current State: National Program of Cancer Registries (NPCR) Information Flow



Future State



Future State: Cloud-based Computing Platform (CBCP) for Real-Time Reporting

Advantages

- Shorten time from case identification to completed incidence record available in CCR database
- Shift CCR staff work to spend less time on file processing, running multiple separate applications, and tracking down missing data, to more productive tasks

Vision

- Labs send electronic pathology reports in real time to cloud-based service
- Service automatically processes these reports by extracting and coding salient data elements

Future State: Cloud-based Computing Platform (CBCP) for Real-Time Reporting

CBCP initiates abstracting process by automatically notifying the ordering facility to request that they complete partial abstract created by CBCP

Facility completes abstract via the cloud service(s)

Dashboard interface to monitor abstracting and automatically send completed abstract to CCR, where it enters the usual reporting stream.

• For these reports, minimal to no CCR staff time is needed

10 Division for Cancer Prevention and Control

Future State: Cloudbased Computing Platform (CBCP) for **Real-Time** Reporting



Future State: Cloud-based Computing Platform (CBCP) for Follow-Back by the Central Cancer Registry (CCR)



Future State: Dashboard Example



CBCP for Real-time Reporting Advantages

CBCP for Real-time Reporting Advantages

Coordinated funding	No siloed projects	Shared governance
Vetting of innovative concepts	Unified interface and single portal for pathology laboratories and EHR vendors	Reduced costs: cost sharing and lower direct costs
Native advanced security	Language neutral	Service can be used by other disease domains

Shared Services



Cancer Surveillance Modernization

A cloud-based Platform of **shared services** allows different organizations to develop and support a **service**. These services can work in concert as a **fully functional system**.

		Cloud Services	Cancer	Other Disease Domains	
		Laboratory Information System Interface	Х	Х	
		Data Transport Service	Х	Х	
	NLP	NLP/Machine Learning Service	Х	Х	
		Patient Matching, Record Linkage, and Deduplication	X	Х	
	l _p S	ePath Report Processing / Analysis	Х	Х	
		EHR Report Processing / Analysis	Х	Х	
	I	Web-based Abstracting Service	Х	Х	
	staar N N	Interface with Vendor-based Hospital Registry	Х	Х	
7 Division for Car	n.,				

Laboratory Information System Interface Service





19 Division for Cancer Prevention and Control

Patient Matching, Record Linkage, and Deduplication Service



20 Division for Cancer Prevention and Control



Web-based Abstracting Service

Web Plus						Any State Cancer Registry email: WebPlusHelp@state.gov 999-999-9999		
Home	New Abstract Find	Open Abstract	Release Abstracts	Reports	Change Password	Help	Log out	
Update abstract		<i> S</i> umr Select a	mary Stage 2018 - Internet Explorer code from the table below:				– 🗆 X	
All data items marked with an and strate current of the s	asterisk (*) are required.	**Prost develop (https:// (https:// (https:// (2017)) **Note 8935-85 the pros clinical informa prostate **Note which n prostate disease	ate** 8000-8700, 8720-8790, 9 ment of this chapter * SEER E //seer.cancer.gov/archive/manue //seer.cancer.gov/tools/ssm/ssm cancerstaging.org/cstage/Pages published by Springer Internati 2:** See the following chapter 936: *GIST* * 9140: *Kaposi static urethra (C680). **Note 4 extension unless the physician ation from the DRE, but the phy- e is "firm." Physician stages the 7:** Involvement of prostatic means tumor extends to pelvic sectomy for other reasons (for ex- found.	9700-9701 C619 C619 I Extent of Disease 1988: dis/EOD10Dig.3rd.pdf) 2000/) * Collaborative S /default.aspx * Chapter onal Publishing. Used v rs for the listed histologi Sarcoma* **Note 3:** ; ** Assign code 1 when clearly incorporates im ysician assigns a clinica patient as a cT2a. The urethra does not alter th sidewall(s) (code 7). **] cample, a cystoprostated	Prostate gland **Note 1: Codes and Coding Instru * SEER Summary Stagi Stage Data Collection Sy 58 *Prostate*, in the AJ with permission of the A: ies * 8710-8714, 8800-8 See the *Urethra* chapta in there is only a TURP. * laging findings into their 1 extent of disease, the re T2a (localized) can be u the Summary Stage code. Note 9:** When prostate ctomy for bladder cancer	** The following sources v ictions (3rd Edition, 1998) ng Manual-2000: Codes an estem, version 02.05: CC Cancer Staging Manua merican College of Surgeo 934, 8940-9137, 9141-958 er for transitional cell (urot *Note 5.** Imaging is not evaluation. **Note 6:** If egistrar can use that. * *Ex sed since the physician has **Note 8:** "Frozen pelvi e cancer is an incidental fin), use the appropriate code	were used in the ad Coding Instruction 1, Eighth Edition ns, Chicago, Illinois. 2: *Soft Tissue** helial) carcinoma of used to determine th f there is no ample:* DRE reveals documented this. s" is a clinical term ding during a for the extent of	
Summary Stage 1077		\$\$2018			Description			
		<u>0</u>	In situ, intraepithelial, noninvasive					
TNMEdition		1	Localized only (localized, NOS) - Cl (but not beyond) prostatic capsule -	inically apparent or inappare No extracapsular extension	ent tumor - Confined to prostat - One or more lobes involved	e, NOS - Intracapsular involvem	ent only - Invasion into	
TEXT - DIAGNOSIS Physical Exam		2	Regional by direct extension only - capsule), unilateral, bilateral, NOS - Rectovesical (Denonvillier's) fascia	Bladder neck - Bladder, NOS Extraprostatic urethra (mem - Rectum - Seminal vesicles	6 - External sphincter - Extrap nbranous urethra) - Fixation, N - Skeletal muscle - Through o	rostatic/extracapsular extension IOS - Levator muscles - Peripros apsule, NOS - Ureter(s)	(beyond prostate static tissue -	
PT PRESENTED IN 2018 WIT & HIGHPSA. HAS HAD URIN	H ABNORMAL DRE	<u>3</u>	Regional lymph node(s) involved or Sacral, NOS + Lateral (laterosacral)	ly - Hypogastric - Iliac, NOS) + Middle (promontory) (Ger	+ External + Internal (hypoga ota's node) + Presacral - Reg	stric) (obturator), NOS - Pelvic, ional lymph node(s), NOS + Lyn	NOS - Periprostatic - nph node(s), NOS	
Lab Tests		4	Regional by BOTH direct extension	AND regional lymph node(s)) involved - Codes (2) + (3)			
		Z	Distant site(s)/lymph node(s) involv bone + "Frozen pelvis", NOS + Oth (lateral [lumbar], para-aortic, periao inguinal) + Superficial (femoral) + R NOS + Carcinomatosis + Distant m	ed - Distant site(s) (including er organs + Penis + Sigmoid rtic, NOS) + Cervical + Comr etroperitoneal, NOS + Scaler etastasis WITH or WITHOUT	further contiguous extension) colon + Soft tissue other than mon iliac + Inguinal (deep, NC ne (inferior deep cervical) + Si f distant lymph node(s)) + Bone + Extension to or fixatio periprostatic - Distant lymph no S) * Node of Cloquet or Rosenn upraclavicular (transverse cervic	n to pelvic wall or pelvic de(s), NOS + Aortic nuller (highest deep al) - Distant metastasis,	
Save Click to save the	e abstract and run data Edits. See	th 9	Unknown if extension or metastasis					Ť
Caro		<					>	

ePath Report Processing/Analysis Service



22 Division for Cancer Prevention and Control

EHR Report Processing/Analysis Service

R	Eile Administration Help	s 🍰 Export Abstracts 😭 PHINM	15 Queue 🔎 Search 📄 Raw Da	ta 📑 Reports			Auto-generated Abstract	- 1
DA It	Back Next Stylesheet View Processin	ng Log 🍓 Print			T	Print 🚸 View Merged Record	i Results	
	≯					AbsrefID: 6	*	
	Patient Information							
	Date/Time of Report	20120225		Mapped		PATIENT IDENTIFICATION		
	Patient's First Name	Amy		Voluco		NameLast	Fowler	
	Patient's Last Name	Fowler		Values		NameFirst	Amy	
	Patient's Middle Name	Farrah		(direct)	· · · ·	NameMiddle	Farrah	
	Patient Name Suffix					Name Maiden		
	Patient Maiden Name	King				Name-Maiden		
	Patient Name Alias					NameAlias	1	
	1 of 2					NamePrefix		
	Patient's Street Address	4732 Charles Avenue				NameSuffix	[
	Patient Street Address Supplemental					Name-Spouse/Parent		
	Patient's City	Madison				Name=Spouse/Farent	1	
	Patient's State	WI		Translated		Social Security Number	325829876	
	Patient's Zipcode	53705		Value	_	Sex	2 Female	-
	Patient's County			value		Date of Birth	19640922	
	Patient's Country	USA			+	Date of Birth Flag		
	Patient's Address Start Date	20010401					All of part of date known OK d	ate not 💌
	Patient's Address End Date	20110630	Mapped Values			DEMOGRAPHICS		
	2 of 2		(complex rules)			Addr at DXNo Street	14979 Main Street	
	Patient's Street Address	14979 Main Street	(complex rules)			Addr at DXSupplementi		
	Patient Street Address Supplemental					Addr at DXCity	Menomonie	
- II '	Patient's City	Menomonie				Addr at DX_State		
	Patient's State	51751		Defaulted			VVI VVIsconsin	<u> </u>
	Patient's Zipcode	54751		Value		Addr at DXPostal Code	54751	
	Patient's County	1104		Fundo		County at DX	999	
	Patient's Address Start Date	20110701				Addr CurrentNo Street	14979 Main Street	
	Patient's Address Start Date	20110701			_	Addr Current-		
	Patient's Address Lise					Supplementi	1	
	Patient's Phone Number	tel:/262)9934711				Addr CurrentCity	Menomonia	
	Patient's Cender	Eemale						
	Patient's Gender Code	F				Addr Current-State	WI Wisconsin	-
- I - '	Patient's Date of Birth	19640922				Addr CurrentPostal	54751	
	Patient's Medical Record Number	3259/1988				Code		
	Patient's Social Security Number	325-82-0876				Addr CurrentCountry	USA	
	Patient's Base Display Name	525-62-9870				CountyCurrent	999	
	Fatient's Race Display Name	Amcan American					-	

23 Division for Cancer Prevention and Control

NLP/Machine Learning Service



NLP Use Cases for the Cancer Domain



Interface with Vendor-based Hospital Registry Service



25 Division for Cancer Prevention and Control

Reliable. Trusted. Scientific.

LECTRONIC

NTERCHANGE

DATA

Value of the Cloud and Real-time Data

Value of the Cloud and Real-time Data

- Much faster identification of cancer cases to evaluate and improve cancer control strategies and program planning
- Find out what interventions work or don't and adjust quickly
- Better-informed decisions about where resources need to be allocated
- Timelier identification of cancer patients cases for clinical trials
- Quickly identify where research needs are
- A model for real-time reporting of other chronic and infectious disease data



Central Cancer Registry (CCR) Question and Answers

- Q: Where is the data stored in the cloud and for how long?
- A: When a request for proposal (RFP) is issued, the standards for server use and location can be stipulated. The CCR can determine how long that data is stored in the cloud (rule-based levels).

Central Cancer Registry (CCR) Question and Answers (continued)

• Q: Where is the data stored in the cloud and for how long?

Best	Consolidate reports from multiple facilities and route to CCR database management system
Better	Parse report, create a partial abstract, prompt a single facility to complete the abstract, route to CCR database management system
Good	Parse report and route to CCR database management system

Central Cancer Registry (CCR) Question and Answers (continued)

- Q: How will the cloud be governed and how will data access be controlled?
- A: A governance team will be made up of CCR representatives and other stakeholders. The CCR will have full control of their data via roles set up for each CCR administrator.

Central Cancer Registry (CCR) Question and Answers (continued)

- Q: What role will the CCR and CCR database management system have once the cloud is fully implemented?
- A: The CCR and its database management system will continue in its current role; however, the focus will be on case-finding, linking, consolidation, and quality control efforts. The cloud will focus on automating upstream processes and creating real-time data access.

Project Leadership:

- Wendy Blumenthal, MPH, Health Scientist
- Sandy Jones, Public Health Advisor



"The best way to predict your future is to create it" — Abraham Lincoln



Thank you!

Go to the official federal source of cancer prevention information: www.cdc.gov/cancer





Division of Cancer Prevention and Control Reliable. Trusted. Scientific.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.